Area of research
Surgery · Oncology
Research interest
Research interests include Cholangiocarcinoma and Gallbladder Cancer Studies, Hepatocellular Carcinoma Treatment and Prognosis, Gallbladder and Bile Duct Disorders, and Pancreatic and Hepatic Oncology Research.
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions.
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study
Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study
Cholangiocarcinoma and Occupational Exposure to Asbestos: Insights From the Italian Pooled Cohort Study
O-177 OCCUPATIONAL EXPOSURE TO ASBESTOS AND CHOLANGIOCARCINOMA: PRELIMINARY RESULTS FROM THE CARA CASE-CONTROL STUDY
The Italian Rare Biliary tract Cancer initiative (IRaBiCa): A multicentric observational study of Gruppo Oncologico dell’Italia Meridionale (GOIM) in collaboration with Gruppo Italiano Colangiocarcinoma (GICO)
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
Pleural mesothelioma risk in the construction industry: a case–control study in Italy, 2000–2018
Pleural mesothelioma risk in the construction industry: a case-control study in Italy, 2000-2018.
Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study
Supplementary Methods from Golgi Acidification by NHE7 Regulates Cytosolic pH Homeostasis in Pancreatic Cancer Cells
Data from Golgi Acidification by NHE7 Regulates Cytosolic pH Homeostasis in Pancreatic Cancer Cells
Supplementary Methods from Golgi Acidification by NHE7 Regulates Cytosolic pH Homeostasis in Pancreatic Cancer Cells
Supplementary Figures from Golgi Acidification by NHE7 Regulates Cytosolic pH Homeostasis in Pancreatic Cancer Cells
Data from Golgi Acidification by NHE7 Regulates Cytosolic pH Homeostasis in Pancreatic Cancer Cells
Supplementary Figures from Golgi Acidification by NHE7 Regulates Cytosolic pH Homeostasis in Pancreatic Cancer Cells
Exposure to Asbestos and Increased Intrahepatic Cholangiocarcinoma Risk: Growing Evidences of a Putative Causal Link
Exposure to Asbestos and Increased Intrahepatic Cholangiocarcinoma Risk: Growing Evidences of a Putative Causal Link.
FGFR Inhibitors in Cholangiocarcinoma: A Real-World Experience at a Tertiary Center.
Assessing the impact of COVID-19 on liver cancer management (CERO-19)
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma
Heterotopic segmental liver transplantation on splenic vessels after splenectomy with delayed native hepatectomy after graft regeneration: A new technique to enhance liver transplantation.
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy
Current and novel therapeutic opportunities for systemic therapy in biliary cancer
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2
Golgi Acidification by NHE7 Regulates Cytosolic pH Homeostasis in Pancreatic Cancer Cells.
Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha‐fetoprotein after sorafenib in REACH and REACH‐2